Loan Loss Reserves / Non-Performing Loans (Annual)

Loan Loss Reserves / Non-Performing Loans: Allowance for bad loans as a portion of total loans made. Calculated as: Loan Loss Reserves / Non-Performing Loans

Royalty Pharma PLC (RPRX) Loan Loss Reserves / Non-Performing Loans data is not available.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$2.38B
Net Income	$770.95M
Cost of Goods Sold	--
Gross Profit	$2.38B
Operating Expenses	$818.67M
Operating Income	$1.56B
Non-Operating Income/Expense	$-235.33M
Pre-Tax Income	$1.32B
Normalized Pre-Tax Income	$1.28B
Income after Taxes	$1.32B
Income from Continuous Operations	$1.32B
Consolidated Net Income/Loss	$1.32B
Normalized Income after Taxes	$1.28B
EBIT	$1.56B
EBITDA	$1.59B
Weighted-Average Shares Outstanding (Basic)	429.80M
Weighted-Average Shares Outstanding (Diluted)	564.46M
Earnings per Share (EPS) (Basic)	$1.79
Earnings per Share (EPS) (Diluted)	$1.78
Balance Sheet Financials
Current Assets	$1.53B
Property, Plant, and Equipment	$16.21B
Long-Term Assets	$18.09B
Total Assets	$19.62B
Current Liabilities	$636.21M
Long-Term Debt	$8.57B
Long-Term Liabilities	$9.27B
Total Liabilities	$9.91B
Common Equity	$9.71B
Tangible Shareholders Equity	$8.79B
Shareholders Equity	$9.71B
Common Shares Outstanding	988.63M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$2.49B
Cash Flow from Investing Activities	$-1.61B
Cash Flow from Financial Activities	$-1.19B
Beginning Cash	$929.03M
End Cash	$618.70M
Increase/Decrease in Cash	$-310.33M
Stock-Based Compensation	$289.89M
Common Stock Dividends Paid	$-900.63M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.40
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.47
Debt to Equity Ratio	0.92
Gross Margin	100.00%
Operating Margin	65.58%
EBIT Margin	65.58%
EBITDA Margin	66.94%
Pre-Tax Profit Margin	55.68%
Profit Margin	32.42%
Free Cash Flow	$2.49B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	--
Receiveable Turnover	81.12
Days Sales in Receivables	4.50
Return on Equity	13.63%
Return on Tangible Equity	15.06%
Return on Assets	6.75%
Return on Investments	7.24%
Book Value Per Share	$9.83
Free Cash Flow per Share	$4.41
Operating Cash Flow per Share	$4.41

Data from Zacks Investment Research, Inc.